9.36
+0.38(+4.23%)
Currency In USD
| Previous Close | 8.98 |
| Open | 9.14 |
| Day High | 9.5 |
| Day Low | 9.07 |
| 52-Week High | 14.44 |
| 52-Week Low | 5.22 |
| Volume | 1.04M |
| Average Volume | 1.18M |
| Market Cap | 803.97M |
| PE | -16.42 |
| EPS | -0.57 |
| Moving Average 50 Days | 9.38 |
| Moving Average 200 Days | 9.38 |
| Change | 0.38 |
If you invested $1000 in Anavex Life Sciences Corp. (AVXL) 10 years ago, it would be worth $1,046.98 as of October 21, 2025 at a share price of $9.36. Whereas If you bought $1000 worth of Anavex Life Sciences Corp. (AVXL) shares 5 years ago, it would be worth $1,817.48 as of October 21, 2025 at a share price of $9.36.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’
GlobeNewswire Inc.
Oct 10, 2025 11:30 AM GMT
Presentation title: “Advancing Alzheimer’s Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine” NEW YORK, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinic
Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program
GlobeNewswire Inc.
Oct 02, 2025 11:35 AM GMT
ANAVEX3-71-002 trial achieved its primary endpoint demonstrating safety and tolerability in both male and female adults Oral ANAVEX®3-71 tablet exhibits superior pharmacokinetics compared to the current immediate-release oral capsule, enabling once-d
Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
GlobeNewswire Inc.
Oct 02, 2025 11:30 AM GMT
ANAVEX3-71-SZ-001 achieved its primary endpoint demonstrating safety and tolerability in adults with schizophrenia Encouraging trends observed in biomarkers support continued development NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Anavex Life Scien